Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/09/18
End: 05/02/19
Due: 05/02/20
Phase: N/A
Priority: Normal
Start: 10/31/16
End: 12/31/16
Due: 12/31/17
Phase: N/A
Priority: Normal
Start: 02/19/18
End: 01/30/19
Due: 01/30/20
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) | NCT03594058 | Velicept Therapeutics, Inc. | user2@example.com | None | 2018-07-09 | 2019-05-02 | 2020-05-02 | - | - | 2025-07-14 |
| Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects | NCT02938507 | Velicept Therapeutics, Inc. | user2@example.com | None | 2016-10-31 | 2016-12-31 | 2017-12-31 | - | - | 2025-07-14 |
| Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women | NCT03475706 | Velicept Therapeutics, Inc. | user2@example.com | None | 2018-02-19 | 2019-01-30 | 2020-01-30 | - | - | 2025-07-14 |